LAUSR

Main Results We included 7 trials with a total of 735 participants. Three trials, involving 371 participants, analyzed effects of RIC on IS prevention. In patients with symptomatic intracerebral artery stenosis, recurrent IS was significantly reduced by RIC (risk ratio, 0.32; 95% CI, 0.12–0.83; Figure [A]). In patients undergoing carotid stenting, pretreatment of RIC significantly lower stroke severity (mean difference, −0.17 mL; 95% CI, −0.23 to −0.11). However, adverse events were significantly higher in participants treated with RIC (risk ratio, 10.91; 95% CI, 2.01–59.28). Four trials, involving 364 participants, analyzed effects of RIC on IS treatment. In patients with acute stroke undergoing intravenous thrombolysis, the death or dependency rate was significantly associated with RIC (risk ratio, 2.34; 95% CI, 1.19– 4.61; Figure [B]). RIC did not significantly affect stroke severity (standardized mean difference, −0.24 mL; 95% CI, −1.02 to 0.54), psychological (standardized mean difference, −0.37 points; 95% CI, −1.15 to 0.41), and cognitive function (standardized mean difference, −0.26 points; 95% CI, −0.72 to 0.21).